5 Drugs Stocks Driving The Industry Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 161 points (1.0%) at 15,537 as of Monday, Sept. 16, 2013, 12:45 PM ET. The NYSE advances/declines ratio sits at 2,425 issues advancing vs. 535 declining with 80 unchanged.

The Drugs industry currently sits up 1.0% versus the S&P 500, which is up 0.9%. Top gainers within the industry include Regeneron Pharmaceuticals ( REGN), up 1.9%, Valeant Pharmaceuticals International ( VRX), up 1.7%, Novo Nordisk A/S ( NVO), up 1.7%, AstraZeneca ( AZN), up 1.6% and Eli Lilly and Company ( LLY), up 0.9%.

TheStreet would like to highlight 5 stocks pushing the industry higher today:

5. Biogen Idec ( BIIB) is one of the companies pushing the Drugs industry higher today. As of noon trading, Biogen Idec is up $5.00 (2.1%) to $239.71 on average volume. Thus far, 508,140 shares of Biogen Idec exchanged hands as compared to its average daily volume of 1.3 million shares. The stock has ranged in price between $236.31-$240.20 after having opened the day at $238.03 as compared to the previous trading day's close of $234.71.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $55.6 billion and is part of the health care sector. Shares are up 59.9% year to date as of the close of trading on Friday. Currently there are 12 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, impressive record of earnings per share growth and compelling growth in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Biogen Idec Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

4. As of noon trading, Bristol-Myers Squibb Company ( BMY) is up $1.69 (3.9%) to $45.25 on heavy volume. Thus far, 5.5 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 7.4 million shares. The stock has ranged in price between $44.37-$45.42 after having opened the day at $44.48 as compared to the previous trading day's close of $43.56.

Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Bristol-Myers Squibb Company has a market cap of $71.9 billion and is part of the health care sector. Shares are up 34.0% year to date as of the close of trading on Friday. Currently there are 6 analysts that rate Bristol-Myers Squibb Company a buy, 1 analyst rates it a sell, and 12 rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its good cash flow from operations, expanding profit margins, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Bristol-Myers Squibb Company Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Amgen ( AMGN) is up $1.33 (1.2%) to $116.39 on average volume. Thus far, 2.2 million shares of Amgen exchanged hands as compared to its average daily volume of 3.3 million shares. The stock has ranged in price between $115.41-$116.89 after having opened the day at $116.21 as compared to the previous trading day's close of $115.06.

Amgen, the world's largest independent biotechnology company, was founded in Thousand Oaks, California in 1980 as AMGen (Applied Molecular Genetics). Amgen has a market cap of $85.5 billion and is part of the health care sector. Shares are up 31.6% year to date as of the close of trading on Friday. Currently there are 8 analysts that rate Amgen a buy, no analysts rate it a sell, and 12 rate it a hold.

TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, reasonable valuation levels, solid stock price performance and growth in earnings per share. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Amgen Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Merck ( MRK) is up $0.56 (1.2%) to $48.35 on light volume. Thus far, 4.4 million shares of Merck exchanged hands as compared to its average daily volume of 12.3 million shares. The stock has ranged in price between $48.10-$48.44 after having opened the day at $48.25 as compared to the previous trading day's close of $47.79.

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide. Merck has a market cap of $140.0 billion and is part of the health care sector. Shares are up 16.9% year to date as of the close of trading on Friday. Currently there are 8 analysts that rate Merck a buy, 1 analyst rates it a sell, and 6 rate it a hold.

TheStreet Ratings rates Merck as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Merck Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Johnson & Johnson ( JNJ) is up $0.64 (0.7%) to $89.22 on light volume. Thus far, 3.3 million shares of Johnson & Johnson exchanged hands as compared to its average daily volume of 9.5 million shares. The stock has ranged in price between $89.00-$89.57 after having opened the day at $89.43 as compared to the previous trading day's close of $88.57.

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Johnson & Johnson has a market cap of $250.8 billion and is part of the health care sector. Shares are up 27.0% year to date as of the close of trading on Friday. Currently there are 10 analysts that rate Johnson & Johnson a buy, no analysts rate it a sell, and 9 rate it a hold.

TheStreet Ratings rates Johnson & Johnson as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Johnson & Johnson Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).
null

If you liked this article you might like

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

It's a Flash Sale!: Cramer's 'Mad Money' Recap (Wednesday 1/31/18)

It's a Flash Sale!: Cramer's 'Mad Money' Recap (Wednesday 1/31/18)

These 2 Biotech Stocks Still Have Upside

These 2 Biotech Stocks Still Have Upside

Building in Biotech, Adding to Twitter

Building in Biotech, Adding to Twitter

Biogen, Celgene Jump on Earnings; Ford's Acquisitions Fail to Move Stock--ICYMI

Biogen, Celgene Jump on Earnings; Ford's Acquisitions Fail to Move Stock--ICYMI